These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34645477)

  • 21. The cascade of care for opioid use disorder among youth in British Columbia, 2018.
    Krebs E; Min JE; Zhou H; Davison C; McGowan G; Nosyk B
    J Subst Abuse Treat; 2021 Nov; 130():108404. PubMed ID: 34118696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial.
    Thompson RG; Bollinger M; Mancino MJ; Hasin D; Han X; Bush KA; Kilts CD; James GA
    Trials; 2023 Apr; 24(1):255. PubMed ID: 37016394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.
    Saunders EC; Budney AJ; Cavazos-Rehg P; Scherer E; Bell K; John D; Marsch LA
    J Subst Use Addict Treat; 2024 Aug; 163():209383. PubMed ID: 38670531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study.
    Welsh JW; Mataczynski MJ; Passetti LL; Hunter BD; Godley MD
    Am J Drug Alcohol Abuse; 2022 May; 48(3):347-355. PubMed ID: 35416739
    [No Abstract]   [Full Text] [Related]  

  • 26. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
    Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
    J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medications for opioid use disorder in pregnancy in a state women's prison facility.
    Knittel AK; Zarnick S; Thorp JM; Amos E; Jones HE
    Drug Alcohol Depend; 2020 Sep; 214():108159. PubMed ID: 32683223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts.
    Shrestha S; Stopka TJ; Hughto JMW; Case P; Palacios WR; Reilly B; Green TC
    Drug Alcohol Depend; 2024 Jun; 259():111293. PubMed ID: 38643530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Peer Recovery Coach Intervention for Hospitalized Patients with Opioid Use Disorder: A Pilot Randomized Controlled Trial.
    Suzuki J; Martin B; Loguidice F; Smelson D; Liebschutz JM; Schnipper JL; Weiss RD
    J Addict Med; 2023 Sep-Oct 01; 17(5):604-607. PubMed ID: 37788617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
    Nayak SM; Huhn AS; Bergeria CL; Strain EC; Dunn KE
    Drug Alcohol Depend; 2021 Apr; 221():108649. PubMed ID: 33640679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
    Friesen EL; Kurdyak P
    Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of social connection in opioid use disorder treatment engagement.
    Schweitzer EM; Urmanche A; Kong J; Hafezi S; Zhao J; Cooperman NA; Konova AB
    Psychol Addict Behav; 2024 Mar; 38(2):222-230. PubMed ID: 37384450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
    Andraka-Christou B; Atkins D; Madeira J; Silverman RD
    Drug Alcohol Rev; 2020 Jul; 39(5):583-587. PubMed ID: 32394525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.
    Craft WH; Tegge AN; Keith DR; Shin H; Williams J; Athamneh LN; Stein JS; Chilcoat HD; Le Moigne A; DeVeaugh-Geiss A; Bickel WK
    Drug Alcohol Depend; 2022 May; 234():109389. PubMed ID: 35287034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration.
    Gordon AJ; Saxon AJ; Kertesz S; Wyse JJ; Manhapra A; Lin LA; Chen W; Hansen J; Pinnell D; Huynh T; Baylis JD; Cunningham FE; Ghitza UE; Bart G; Yu H; Sauer BC
    Drug Alcohol Depend; 2023 Jul; 248():109902. PubMed ID: 37196572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.